Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up : Results of a randomized controlled trial (SCHEDULE)

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: WFRF:(Arora K) > Effect of everolimu...

LIBRIS Formathandbok (Information om MARC21)

Fältnamn	Indikatorer	Metadata
000		05123naa a2200541 4500
001		oai:lup.lub.lu.se:afe0c122-cb37-433f-8620-f43c4d2fec2c
003		SwePub
008		170824s2017 \| \|\|\|\|\|\|\|\|\|\|\|000 \|\|eng\|
009		oai:DiVA.org:liu-141127
024	7	a https://lup.lub.lu.se/record/afe0c122-cb37-433f-8620-f43c4d2fec2c2 URI
024	7	a https://doi.org/10.1111/ctr.130382 DOI
024	7	a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1411272 URI
040		a (SwePub)lud (SwePub)liu
041		a engb eng
042		9 SwePub
072	7	a art2 swepub-publicationtype
072	7	a ref2 swepub-contenttype
100	1	a Relbo Authen, Anneu Oslo university hospital,National Hospital Norway, Norway4 aut
245	1 0	a Effect of everolimus vs calcineurin inhibitors on quality of life in heart transplant recipients during a 3-year follow-up : Results of a randomized controlled trial (SCHEDULE)
264		c 2017-07-19
264	1	b Wiley,c 2017
520		a The Scandinavian heart transplant everolimus de novo study with early calcineurin inhibitors avoidance (SCHEDULE) trial was a 12 month, randomized, open-label, parallel-group trial that compared everolimus (EVR; n=56) to conventional CsA (n=59) immunosuppression. Previously, we reported that EVR outperformed CsA in improving renal function and coronary artery vasculopathy, despite a higher rejection rate with EVR. This study aimed to compare the effects of these treatments on quality of life (QoL). Within five post-operative days, patients (mean age 50±13 years, 27% women) were randomized to EVR or a standard CsA dosage (CsA group). This study assessed quality of life (QoL), based on the Short Form-36, EuroQol-5D, and Beck Depression Inventory (BDI). Assessments were performed pre-HTx and 12 and 36 months post-HTx. At 12 and 36 months, the groups showed similar improvements in Short Form-36 measures (at pre-HTx, 12 and 36 months the values were as follows: Physical component summary: EVR: 31.5±110.9, 49.1±9.7, and 47.9±10.6; P<.01; CsA: 32.5±8.2, 48.4±8.5, and 46.5±11.5; P<.01; mental component summary: EVR: 46.0±12.0, 51.7±11.9, and 52.1±13.0; P<.01; CsA: 38.2±12.5, 53.4±7.1, and 54.3±13.0; P<.01); similar decrease in mean BDI (EVR: 10.9±10.2, 5.4±4.7, and 8.1±9.0; P<.01; CsA: 11.8±7.1, 6.3±5.4, and 6.2±6.5; P<.01); and similar Euro Qol-improvements. Thus, in this small-sized study, EVR-based and conventional CsA immunosuppressive strategies produced similar QoL improvements.
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
650	7	a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650	7	a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
653		a Heart transplantation
653		a Immunosuppression
653		a Quality of life
653		a heart transplantation; immunosuppression; quality of life
700	1	a Grov, Ingelinu Oslo university hospital,National Hospital Norway, Norway4 aut
700	1	a Karason, Kristjanu Sahlgrens University Hospital, Sweden,National Hospital Norway, Norway; University of Oslo, Norway4 aut
700	1	a Gustafsson, Finnu Copenhagen University Hospital,Rigshosp, Denmark4 aut
700	1	a Eiskjær, Hansu Aarhus University Hospital, Denmark4 aut
700	1	a Rådegran, Göranu Lund University,Lunds universitet,Kardiologi,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Hjärt-lungsjukdom - information, stöd och bemötande,Forskargrupper vid Lunds universitet,Lund Hemodynamic Lab,Cardiology,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Cardiopulmonary disease - information, support and reception,Lund University Research Groups,Skåne University Hospital,Lund University, Sweden;4 aut0 (Swepub:lu)med-grd
700	1	a Gude, Einaru Oslo university hospital,National Hospital Norway, Norway4 aut
700	1	a Jansson, Kjellu Linköpings universitet,Linköping University,Avdelningen för kardiovaskulär medicin,Hälsouniversitetet,Region Östergötland, Kardiologiska kliniken US4 aut0 (Swepub:liu)kjeja02
700	1	a Dellgren, Göranu Sahlgrens University Hospital, Sweden4 aut
700	1	a Solbu, Dagu Novartis Norge AS, Norway4 aut
700	1	a Arora, Satishu National Hospital Norway, Norway; University of Oslo, Norway4 aut
700	1	a Andreassen, Arne K.u Oslo university hospital4 aut
700	1	a Gullestad, Larsu National Hospital Norway, Norway; University of Oslo, Norway4 aut
710	2	a Oslo university hospitalb National Hospital Norway, Norway4 org
773	0	t Clinical Transplantationd : Wileyg 31:9q 31:9x 0902-0063x 1399-0012
856	4	u http://dx.doi.org/10.1111/ctr.13038y FULLTEXT
856	4 8	u https://lup.lub.lu.se/record/afe0c122-cb37-433f-8620-f43c4d2fec2c
856	4 8	u https://doi.org/10.1111/ctr.13038
856	4 8	u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-141127

Hitta via bibliotek

Clinical Transplantation (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Relbo Authen, An ...; Grov, Ingelin; Karason, Kristja ...; Gustafsson, Finn; Eiskjær, Hans; Rådegran, Göran; visa fler...; Gude, Einar; Jansson, Kjell; Dellgren, Göran; Solbu, Dag; Arora, Satish; Andreassen, Arne ...; Gullestad, Lars; visa färre...

Om ämnet

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kardiologi

MEDICIN OCH HÄLSOVETENSKAP: MEDICIN OCH HÄLS ...; och Klinisk medicin; och Kirurgi

Artiklar i publikationen: Clinical Transpl ...

Av lärosätet: Lunds universitet; Linköpings universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se